Search research articles
Contact Us
Filters
Showing results (271-280 of 320) with videos related to
Page
of 32
Sort By:
Microbial Cell Factories
|
January 30, 2020
Integrating pathway elucidation with yeast engineering to produce polpunonic acid the precursor of the anti-obesity agent celastrol
Nikolaj L Hansen, Karel Miettinen, Yong Zhao, et al.
Breast Cancer Research and Treatment
|
June 5, 2020
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study
S Krajnak, C Schnatz, K Almstedt, et al.
Blood
|
March 9, 2000
Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S
M Makris, M Leach, N J Beauchamp, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
December 2, 2017
On the Structure and Reaction Mechanism of Human Acireductone Dioxygenase
Anna Miłaczewska, Ewa Kot, José A Amaya, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 13, 2010
Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A
A Dmoszynska, A Hellmann, T Baglin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 5, 2011
Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A
A Dmoszynska, K Kuliczkowski, A Hellmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 19, 2014
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
D Matino, D Lillicrap, J Astermark, et al.
Biochemistry
|
August 19, 2025
Provision of a Redox Donor to Oxy-Ferrous PrnB Is Required for Pyrrolnitrin Synthesis
R Brian McMillan, Hannah E Gering, Anastasia E Ledinina, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 3, 2011
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use
E Berntorp, D Keeling, M Makris, et al.
Blood
|
October 9, 1998
Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation
N J Beauchamp, R N Pike, M Daly, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 320) with videos related to
Sort By:
Page
of 32
Microbial Cell Factories
|
January 30, 2020
Integrating pathway elucidation with yeast engineering to produce polpunonic acid the precursor of the anti-obesity agent celastrol
Nikolaj L Hansen, Karel Miettinen, Yong Zhao, et al.
Breast Cancer Research and Treatment
|
June 5, 2020
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study
S Krajnak, C Schnatz, K Almstedt, et al.
Blood
|
March 9, 2000
Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S
M Makris, M Leach, N J Beauchamp, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
December 2, 2017
On the Structure and Reaction Mechanism of Human Acireductone Dioxygenase
Anna Miłaczewska, Ewa Kot, José A Amaya, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 13, 2010
Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A
A Dmoszynska, A Hellmann, T Baglin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 5, 2011
Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A
A Dmoszynska, K Kuliczkowski, A Hellmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
February 19, 2014
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
D Matino, D Lillicrap, J Astermark, et al.
Biochemistry
|
August 19, 2025
Provision of a Redox Donor to Oxy-Ferrous PrnB Is Required for Pyrrolnitrin Synthesis
R Brian McMillan, Hannah E Gering, Anastasia E Ledinina, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 3, 2011
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use
E Berntorp, D Keeling, M Makris, et al.
Blood
|
October 9, 1998
Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation
N J Beauchamp, R N Pike, M Daly, et al.
Page
of 32